The Government of Malawi has launched the world’s first malaria vaccine in a landmark pilot programme aimed at combating one of the world’s leading killers.
Drug-resistant strains of gonorrhea, salmonella, Escherichia coli (E. coli) and many other disease-causing agents are flourishing around the world, and the consequences are disastrous—at least 700,000 people die globally as a result of antimicrobial resistance (AMR) annually, according to a 2016 review on antimicrobial resistance commissioned by former UK Prime Minister David Cameron.
During the current Ebola outbreak in the Democratic Republic of Congo (DRC) with 49 total cases and 26 deaths so far, the government of DRC has approved the use for trials starting this week of a new, as-yet unlicensed Ebola vaccine, the rVSV-ZEBOV.
Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health…. Read More ›
Vaccines have enormous impact not just on health, but on keeping people out of poverty, according to a new study led by researchers from Harvard T.H. Chan School of Public Health. They estimated that increased investments in 10 vaccines administered in low-… Read More ›
Critical Collaboration Agreements for Ebola Vaccine Candidates Earn NIAID an Excellence in Technology Transfer Award
In 2014, as the Ebola outbreak escalated, NIAID collaborated with pharmaceutical company GlaxoSmithKline (GSK) on NIAID-planned clinical trials to test Ebola vaccine candidates. Their collaboration exemplifies the flexibility and creativity of the NIAID Technology Transfer and Intellectual Property Office (TTIPO),… Read More ›